IVERIC bio (ISEE) is an innovative biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs. Stifel has a buy rating on the stock with a $22 price target as it hit an all-time high today. Kymera Therapeutics (KYMR) is a clinical stage biopharmaceutical company. Bank of America recently upgraded the stock to a buy rating with a $80 price target. The final stock that George Tsilis discusses is Rexnord (RXN), an industrial company with a process and motion control platform.
10 Sep 2021
Trading 360
18 Apr 2022
Next Gen Investing
27 Jun 2022
Market On Close
20 May 2022
Market On Close
20 May 2022
Trading 360
23 Jun 2022
The Watch List
28 Apr 2022